Clinical Trial Finder

Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.

Filters
Sort by
A Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited CD34+ Human Hematopoietic Stem and Progenitor Cells (EDIT-301) in Subjects With Severe Sickle Cell Disease

The purpose of this study is to evaluate the efficacy, safety and tolerability of treatment with EDIT-301 in adult subjects with severe sickle cell disease (SCD).

Locations

5 United States sites

Age

18 to 50 Years

Phase

Phase 1/Phase 2

LEARN MORE
Evaluation of Left Ventricular Function by Speckle Tracking Echocardiography in Patient Hospitalised in Intensive Care Unit for Vaso-occlusive Crisis

Vaso-occlusive crisis in Sickle cell disease might alter myocardial function through micro vascular obstruction.

Locations

1 France site

Age

> 18 Years

LEARN MORE
Pre-Transplant Immunosuppression and Related Haploidentical Hematopoietic Cell Transplantation for Patients With Severe Hemoglobinopathies

This clinical trial studies the effect of pre-transplant immunosuppression (PTIS) and donor stem cell transplant in treating patients with severe blood diseases (hemoglobinopathies).

Locations

1 United States site

Age

2 to 30 Years

Phase

Early Phase 1

LEARN MORE
Physical Rehabilitation in Adults With Sickle Cell Anemia: Effects on Muscle Function, Functional Capacity and Quality of Life

Sickle cell anemia (SCA) is one of the most neglected diseases worldwide, according to the World Health Organization.

Locations

1 Brazil site

Age

18 to 60 Years

Phase

N/A

LEARN MORE
Hydroxyurea Therapy for Neurological and Cognitive Protection in Pediatric Sickle Cell Anemia in Uganda: A Single Arm Open Label Trial, “BRAIN SAFE II”

Worldwide, an estimated 200,000 babies are born with Sickle Cell Anemia (SCA) annually.

Locations

1 Uganda site

Age

3 to 9 Years

Genotypes

Sickle Cell Anaemia, SCA

Phase

Phase 3

LEARN MORE
Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell Anemia

The investigators will attempt to develop a more accurate equation to estimate eGFR in pediatric and adult sickle cell patients .

Locations

4 United States sites

Age

5 to 50 Years

Genotypes

SCA, HbSS

LEARN MORE
Reduced Intensity Related Donor Peripheral Blood Derived Hematopoietic Progenitor Cell Transplantation for Patients With Severe Sickle Cell Disease

This study is being done to test a transplant method that may have fewer side effects (or less toxic, less harmful) than conventional high dose chemotherapy conditioning-based transplants for children and young adults with Sickle Cell Disease (SCD).

Locations

1 United States site

Age

2 to 25 Years

Phase

Phase 2

LEARN MORE
Preliminary Feasibility and Efficacy of The Balance Program to Reduce the Impact of Pain on Daily Functioning in Pediatric Sickle Cell Disease

Pain is the primary complication of sickle cell disease (SCD), including vaso-occlusive crises and more persistent, chronic pain.

Locations

1 United States site

Age

8 to 17 Years

Genotypes

HbSS, HbSC

Phase

N/A

LEARN MORE
Evaluation of the Safety,Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat

Background: Sickle cell disease (SCD) is a disorder that causes episodes of acute pain and progressive organ damage.

Locations

1 United States site

Age

18 to 70 Years

Genotypes

HbSS

Phase

Phase 1/Phase 2

LEARN MORE
Venous Thrombosis Biomarkers in Sickle Cell Disease and Sickle Cell Trait

Background: Venous thromboembolism (VTE) includes the abnormal clotting of blood in a deep vein of the upper or lower limbs (deep vein thrombosis) that may travel to and block a blood vessel in the lung (pulmonary embolism).

Locations

1 United States site

Age

18 to 80 Years

Genotypes

HbSS, HbSC, HbAS

LEARN MORE